With just a few days left to register for #EASCongress2025, this is your opportunity to be part of vital conversations and gain insights from leading experts in the field of atherosclerosis.
Join us for an enriching and thought-provoking experience 👉 bit.ly/3UYJAKF
#EASCongress is all about learning and meeting people. This year, we’re focusing even more on the networking part. Make sure to download our app - we’re launching a great new feature that helps you connect with others who share your interests, before, during, and after the event.
Paul Ridker giving the Anitschkow lecture of #EASCongress2025
#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social
European Atherosclerosis Society
European Atherosclerosis Society
New study from Kati Öörni’s lab @katioorni.bsky.social at #WRIHelsinki on the effect of icosapent ethyl (IPE) on circulating lipoproteins and their pro-atherogenic properties.👇
Federica Fogacci
Here we go #EASCongress2025
This paper made it to the top of our readership list:
Icosapent ethyl–induced lipoprotein remodeling and its impact on cardiovascular disease risk markers in normolipidemic individuals
@martinalorey.bsky.social @katioorni.bsky.social
insight.jci.org/articles/vie...
Our latest study, published in @insight.jci.org , shows how high-dose icosapent ethyl (IPE), an ethyl ester of eicosapentaenoic acid (EPA) remodels circulating lipoproteins and reduces cardiovascular risk markers in healthy individuals.
insight.jci.org/articles/vie...
Check our newest paper on how IPE (EPA-precursor) supplementation rapidly induces lipoprotein remodeling, and its impact on CVD risk markers in normolipidemic individuals:
insight.jci.org/articles/vie...
@katioorni.bsky.social #MedSky #CVD #Atherosclerosis #ScienceSky #Lipoproteins
Our latest study, published in @insight.jci.org , shows how high-dose icosapent ethyl (IPE), an ethyl ester of eicosapentaenoic acid (EPA) remodels circulating lipoproteins and reduces cardiovascular risk markers in healthy individuals.
insight.jci.org/articles/vie...
